Skip to main content Skip to search Skip to main navigation

EMA: New guideline on the quality of water for pharmaceutical use

On 20 July 2020, EMA published the final 10-page Guideline on the quality of water for pharmaceutical use.
The date of entry into force will be 1 February 2021.

On that date the guideline replaces 

  • the Note for guidance on quality of water for pharmaceutical use from 1 May 2002 

  • the CPMP Position Statement on the quality of water used in the production of vaccines for parenteral use from 20 October 2003.

It takes into account the following interim changes to the European Pharmacopoeia: 

  • the revised monograph on Water for Injection (0169), which offers the possibility of using processes other than distillation for WFI (Water for Injection), e. g. reverse osmosis 

  • new monograph on water for the production of extracts (2249) and 

  • the suppression of the monograph for HPW, highly purified water (1927) 

It also reflects the expectations for the minimum acceptable water quality in the manufacture of active ingredients and medicinal products for human and veterinary use. 

The guideline is to be understood as a guideline for the pharmaceutical use of different water qualities in the manufacture of active substances and medicinal products for use in human and veterinary medicine. The document also applies to ATMPs (Advanced Therapy Medicinal Products) and can in general also be applied to investigational medicinal products (IMPs).

Chapter 5 “Quality of Water for Pharmaceutical Use” contains tables with examples for different water qualities such as 

  • Water present as an excipient in the final formulation 

  • Water used during manufacture of active substances and medicinal products excluding water present as an excipient in the final formulation 

  • Water used for cleaning/rinsing of equipment, containers and closures 

Read the new guideline together with the corresponding Q&A paper Questions and answers on production of water for injections by nondistillation methods – reverse osmosis and biofilms and control strategies"This Q&A was published in 2017 after the revision of the WFI monograph. 


Source: 

EMA: Guideline on the quality of water for pharmaceutical use 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
Previous
Next